Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 5/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | CTSK | P43235 | 4/20 | 0.55 |
| ▸ | KYNU | Q16719 | 1/20 | 0.55 |
| ▸ | CTSS | P25774 | 3/20 | 0.54 |
| ▸ | CTSL | P07711 | 2/20 | 0.54 |
| ▸ | CTSB | P07858 | 2/20 | 0.54 |
| ▸ | PPARG | P37231 | 1/20 | 0.53 |
| ▸ | PPARA | Q07869 | 1/20 | 0.53 |
| ▸ | TACR1 | P25103 | 2/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | REN | P00797 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8116799 | 1.00 | CASP1 (0.56) | CASP1ALDH1A1ALOX15CTSKKYNU | |
| SCHEMBL3012475 | 1.00 | CASP1 (0.56) | CASP1ALDH1A1ALOX15CTSKKYNU | |
| SCHEMBL12400686 | 0.91 | KYNU (0.62) | CASP1ALDH1A1ALOX15CTSKKYNU | |
| SCHEMBL2617394 | 0.91 | KYNU (0.62) | CASP1ALDH1A1ALOX15CTSKKYNU | |
| SCHEMBL2912589 | 0.91 | CASP1 (0.60) | CASP1ALDH1A1ALOX15CTSKCTSS | |
| SCHEMBL7583002 | 0.91 | CASP1 (0.60) | CASP1ALDH1A1ALOX15CTSKCTSS | |
| SCHEMBL2912586 | 0.91 | CASP1 (0.60) | CASP1ALDH1A1ALOX15CTSKCTSS | |
| SCHEMBL14822417 | 0.89 | CASP1 (0.54) | CASP1ALDH1A1ALOX15CTSKKYNU | |
| SCHEMBL7975561 | 0.89 | CASP1 (0.55) | CASP1ALDH1A1ALOX15CTSKKYNU | |
| SCHEMBL755795 | 0.89 | MMP9 (0.52) | CASP1ALDH1A1ALOX15CTSKKYNU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250025438-A1 | Derivative of aspartic acid and use thereof in treatment of metabolic diseases such as hepatic fibrosis and non-alcoholic hepatitis | SHENZHEN JINGTAI TECHNOLOGY CO., LTD. (CN) | 2025-01-23 | — | — | US | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| CN-118234705-A | Aspartic acid derivative and application thereof in treatment of liver fibrosis, nonalcoholic hepatitis and other metabolic diseases | 深圳利沃生物医药科技有限公司 | 2024-06-21 | — | — | CN | disclosed |
| US-11975076-B2 | Antibody-drug conjugates comprising branched linkers and methods related thereto | LEGOCHEM BIOSCIENCES, INC. (KR) | 2024-05-07 | — | — | US | disclosed |
| EP-3380124-B1 | CONJUGATES COMPRISING SELF-IMMOLATIVE GROUPS AND METHODS RELATED THERETO | LEGOCHEM BIOSCIENCES INC (KR) | 2024-04-03 | — | — | EP | disclosed |
| US-20240011979-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS INC. (KR) | 2024-01-11 | — | — | US | disclosed |
| CN-117244076-A | Conjugates comprising self-degrading groups and methods related thereto | 乐高化学生物科学股份有限公司 | 2023-12-19 | — | — | CN | disclosed |
| CN-116829949-A | Compositions for detecting or measuring analytes | 伯蒂斯有限公司 | 2023-09-29 | — | — | CN | disclosed |
| US-20230234957-A1 | PROTEIN TAG TO INDUCE LIGAND DEPENDENT DEGRADATION OF PROTEIN/PROTEIN-FUSIONS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230234957-A1 | PROTEIN TAG TO INDUCE LIGAND DEPENDENT DEGRADATION OF PROTEIN/PROTEIN-FUSIONS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-07-27 | — | — | US | disclosed |
| EP-0346847-B1 | Amino acid derivatives | HOFFMANN LA ROCHE (CH) | 1994-05-11 | — | — | EP | disclosed |
| US-5294713-A | Inhibiting cell adhesion | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-03-15 | — | — | US | disclosed |
| EP-0321479-B1 | ENZYMATIC MEMBRANE METHOD FOR THE SYNTHESIS AND SEPARATION OF PEPTIDES | COCA COLA CO (US) | 1994-03-09 | — | — | EP | disclosed |
| US-5202235-A | Adjustment of equilibrium of charged and uncharged material | THE COCA-COLA COMPANY (US) | 1993-04-13 | — | — | US | disclosed |
| EP-0529858-A1 | 2-Piperazinone compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1993-03-03 | — | — | EP | disclosed |
| US-5157041-A | Viricides | HOFFMANN-LA ROCHE INC. (US) | 1992-10-20 | — | — | US | disclosed |
| US-5037741-A | Dipeptides such as aspartame, diffusion across an ion-rejection membrane | THE COCA COLA COMPANY (US) | 1991-08-06 | — | — | US | disclosed |
| US-5002871-A | Enzymatic membrane method for the synthesis and separation of peptides | THE COCA-COLA COMPANY (US) | 1991-03-26 | — | — | US | disclosed |
| WO-1990012883-A1 | ENZYMATIC MEMBRANE METHOD FOR THE SYNTHESIS AND SEPARATION OF PEPTIDES | THE COCA-COLA COMPANY (US) | 1990-11-01 | — | — | WO | disclosed |
| EP-0346847-A2 | Amino acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1989-12-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11975076-B2 | Antibody-drug conjugates comprising branched linkers and methods related thereto | PA2G4, FCGRT, CLTB | CASP1 4208/4885ALDH1A1 79/4885ALOX15 478/4885 |
| US-20230234957-A1 | PROTEIN TAG TO INDUCE LIGAND DEPENDENT DEGRADATION OF PROTEIN/PROTEIN-FUSIONS | BET1, STUB1, MDM2 | CASP1 3535/4885ALDH1A1 4453/4885ALOX15 4601/4885 |
| US-20250025438-A1 | Derivative of aspartic acid and use thereof in treatment of metabolic diseases such as hepatic fibrosis and non-alcoholic hepatitis | GOT1, GOT2, GLS2 | CASP1 662/4885ALDH1A1 38/4885ALOX15 887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.